Adverse cardiac remodelling after acute myocardial infarction: old and new biomarkers
AE Berezin, AA Berezin - Disease Markers, 2020 - Wiley Online Library
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …
infarction (AMI) does not decrease regardless of implementation of new technologies …
Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers
AE Berezin, AA Berezin - Disease markers, 2020 - pubmed.ncbi.nlm.nih.gov
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …
infarction (AMI) does not decrease regardless of implementation of new technologies …
[引用][C] Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers
AE Berezin, AA Berezin - Disease Markers, 2020 - elibrary.ru
Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.
AE Berezin, AA Berezin - Disease Markers, 2020 - europepmc.org
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …
infarction (AMI) does not decrease regardless of implementation of new technologies …
[PDF][PDF] Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers
AE Berezin, AA Berezin - 2020 - scienceopen.com
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …
infarction (AMI) does not decrease regardless of implementation of new technologies …
Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.
AE Berezin, AA Berezin - Disease Markers, 2020 - go.gale.com
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …
infarction (AMI) does not decrease regardless of implementation of new technologies …
[PDF][PDF] Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers
AE Berezin, AA Berezin - 2020 - researchgate.net
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …
infarction (AMI) does not decrease regardless of implementation of new technologies …
Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.
AE Berezin, AA Berezin - Disease Markers, 2020 - search.ebscohost.com
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …
infarction (AMI) does not decrease regardless of implementation of new technologies …
[HTML][HTML] Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers
AE Berezin, AA Berezin - Disease Markers, 2020 - ncbi.nlm.nih.gov
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …
infarction (AMI) does not decrease regardless of implementation of new technologies …
Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers
AE Berezin, AА Berezin - 2020 - dspace.zsmu.edu.ua
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …
infarction (AMI) does not decrease regardless of implementation of new technologies …